Tandem Diabetes Care (NASDAQ:TNDM) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Key Points

• Tandem beat quarterly expectations: EPS was a loss of $0.10 versus the expected loss of $0.25, while revenue of $283.69 million topped the $265.85 million forecast. Worldwide revenue rose 14% and pump shipments increased 12%; the company maintained its 2026 sales guidance.
• Pharmacy adoption is slower than expected and is expected to weigh on sales into 2027. Tandem said mid- to high-single-digit revenue growth is a reasonable starting point for next year.
• International revenue climbed 26% to a record $93 million. Product development could add future growth, with Mobi Tubeless targeted for launch in the first half of 2027 if cleared by the FDA.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) released its earnings results on Thursday. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.15, FiscalAI reports. The firm had revenue of $283.69 million during the quarter, compared to analyst estimates of $265.85 million. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%.

Here are the key takeaways from Tandem Diabetes Care's conference call:

• Q3 results were strong: worldwide revenue rose 14% to $284 million and pump shipments increased 12%, while gross margin reached 57% and adjusted EBITDA margin was 6%. Tandem maintained its 2026 sales guidance of $1.065 billion–$1.085 billion.
• Pharmacy adoption is progressing more slowly than expected, though formulary coverage reached about 50% and recurring supply economics exceeded baseline expectations. Tandem expects the transition to weigh on sales into 2027 and said mid- to high-single-digit revenue growth is a reasonable starting point for next year.
• International sales rose 26% to a record $93 million, supported by product launches and stronger direct-market performance. Tandem plans to expand direct operations to cover roughly half of its international installed base by the end of 2027.
• Product development could broaden Tandem’s market opportunity: Mobi Tubeless is in late-stage FDA review, with commercial availability targeted for the first half of 2027 if cleared. The company also plans to begin a pivotal trial of its fully closed-loop system by year-end 2026, with a potential launch in 2028.

Tandem Diabetes Care Trading Down 5.6%

Tandem Diabetes Care stock traded down $1.06 during trading hours on Thursday, hitting $17.99. The company had a trading volume of 3,017,671 shares, compared to its average volume of 2,138,888. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. The firm has a market cap of $1.25 billion, a P/E ratio of -19.34 and a beta of 1.59. The company has a 50-day moving average price of $17.81 and a two-hundred day moving average price of $18.91. Tandem Diabetes Care has a 1 year low of $12.26 and a 1 year high of $29.65.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Oppenheimer reissued an "outperform" rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Mizuho set a $18.00 target price on Tandem Diabetes Care in a research note on Tuesday, October 13th. Barclays raised Tandem Diabetes Care to a "hold" rating in a research note on Wednesday, October 7th. William Blair started coverage on Tandem Diabetes Care in a report on Friday, August 21st. They issued an "outperform" rating on the stock. Finally, Truist Financial decreased their price target on Tandem Diabetes Care from $31.00 to $28.00 and set a "buy" rating for the company in a research note on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $27.08.

Insider Activity at Tandem Diabetes Care

In other news, Director Christopher J. Twomey sold 1,700 shares of the firm's stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total transaction of $32,555.00. Following the transaction, the director directly owned 24,434 shares of the company's stock, valued at approximately $467,911.10. This trade represents a 6.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.10% of the company's stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company's products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem's product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.